Is platelet activating factor ( XXXX ) a mediator of endotoxin shock?

@entity35 @entity551 @entity9480 @entity6848
To determine whether endogenous @entity9480 contributes to the pathogenesis of endotoxin shock, @entity6848 , a specific @entity9480 antagonist, was injected i.v. to @entity35 before, simultaneously with or after endotoxin. @entity6848 (5 mg/kg i.v.) injected 5 min before the endotoxin completely inhibited endotoxin (15 mg/kg i.v.)-induced @entity551 , and @entity6848 (0.05-1 mg/kg i.v.) injected 7-10 min after the endotoxin rapidly reversed endotoxin-induced @entity551 . A combination of @entity6848 (10 mg/kg) with endotoxin (5 mg/kg) administered i.v. improved the survival rate for 20 h or more. @entity6848 (0.05-1 mg/kg i.v.) rapidly reversed the @entity9480 (1 microgram/kg i.v.)-induced @entity551 . These findings strongly suggest that endogenous @entity9480 may play a pivotal role in the pathogenesis of endotoxin shock.
